These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 27519968

  • 1. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    María RS, Marta PM, Sonia S, Natalia GG, Tamara M, Ignasi T, Maria MG, Jaime RM, Adolfo DP, Joan A, Xavier N.
    Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
    [Abstract] [Full Text] [Related]

  • 2. Bone health evaluation one year after aromatase inhibitors completion.
    Pineda-Moncusí M, Servitja S, Casamayor G, Cos ML, Rial A, Rodriguez-Morera J, Tusquets I, Diez-Perez A, Garcia-Giralt N, Nogués X.
    Bone; 2018 Dec; 117():54-59. PubMed ID: 30223134
    [Abstract] [Full Text] [Related]

  • 3. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS.
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [Abstract] [Full Text] [Related]

  • 4. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M, Ruschke S, Rohrmeier A, Syväri J, Einspieler I, Seifert-Klauss V, Schmidmayr M, Metz S, Kirschke JS, Rummeny EJ, Zimmer C, Karampinos DC, Baum T.
    BMC Musculoskelet Disord; 2019 Nov 06; 20(1):515. PubMed ID: 31694630
    [Abstract] [Full Text] [Related]

  • 5. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.
    Endocr Relat Cancer; 2016 Apr 06; 23(4):303-12. PubMed ID: 26911377
    [Abstract] [Full Text] [Related]

  • 6. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
    Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.
    Bone; 2016 Sep 06; 90():123-6. PubMed ID: 27018037
    [Abstract] [Full Text] [Related]

  • 7. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study.
    Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D, Lippuner K.
    J Bone Miner Res; 2013 Mar 06; 28(3):449-54. PubMed ID: 23018784
    [Abstract] [Full Text] [Related]

  • 8. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Calcif Tissue Int; 2017 Oct 06; 101(4):396-403. PubMed ID: 28589205
    [Abstract] [Full Text] [Related]

  • 9. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
    Catalano A, Gaudio A, Agostino RM, Morabito N, Bellone F, Lasco A.
    J Endocrinol Invest; 2019 Nov 06; 42(11):1337-1343. PubMed ID: 31127591
    [Abstract] [Full Text] [Related]

  • 10. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P.
    Osteoporos Int; 2015 Jan 06; 26(1):353-60. PubMed ID: 25381047
    [Abstract] [Full Text] [Related]

  • 11. The Trabecular Bone Score Predicts Spine Fragility Fractures in Postmenopausal Caucasian Women Without Osteoporosis Independently of Bone Mineral Density.
    Ripamonti C, Lisi L, Buffa A, Gnudi S, Caudarella R.
    Med Arch; 2018 Feb 06; 72(1):46-50. PubMed ID: 29416218
    [Abstract] [Full Text] [Related]

  • 12. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct 06; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 13. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
    Markopoulos C, Koukouras D, Venizelos V, Karyda I, Xepapadakis G, Misitzis J, Kalogerakos K, Poulakaki F, Natsiopoulos J, Zobolas V, Savidou C, Antonopoulou Z, Tzoracoleftherakis E.
    Breast; 2016 Jun 06; 27():27-34. PubMed ID: 27212697
    [Abstract] [Full Text] [Related]

  • 14. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K.
    Osteoporos Int; 2014 Jul 06; 25(7):1945-51. PubMed ID: 24760244
    [Abstract] [Full Text] [Related]

  • 15. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD.
    Breast Cancer Res Treat; 2011 Dec 06; 130(3):863-70. PubMed ID: 21861101
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K, Blinder VS, Elkin EB.
    J Clin Oncol; 2012 May 01; 30(13):1468-75. PubMed ID: 22370313
    [Abstract] [Full Text] [Related]

  • 17. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study.
    Godang K, Olarescu NC, Bollerslev J, Heck A.
    Eur J Endocrinol; 2016 Aug 01; 175(2):155-64. PubMed ID: 27220351
    [Abstract] [Full Text] [Related]

  • 18. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML, Yao S, Laurent CA, Roh JM, Quesenberry CP, Kushi LH, Lo JC.
    Breast Cancer Res Treat; 2018 Apr 01; 168(2):523-530. PubMed ID: 29249058
    [Abstract] [Full Text] [Related]

  • 19. The lumbar spine age-related degenerative disease influences the BMD not the TBS: the Osteolaus cohort.
    Padlina I, Gonzalez-Rodriguez E, Hans D, Metzger M, Stoll D, Aubry-Rozier B, Lamy O.
    Osteoporos Int; 2017 Mar 01; 28(3):909-915. PubMed ID: 27900426
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal changes in bone mineral density and trabecular bone score in Korean adults: a community-based prospective study.
    Park SY, Kim JH, Choi HJ, Ku EJ, Hong AR, Lee JH, Shin CS, Cho NH.
    Arch Osteoporos; 2020 Jul 03; 15(1):100. PubMed ID: 32621253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.